GLP receptor agonists tied to lower substance use disorder risk in veterans, reducing emergency visits, hospitalizations, and overdose incidents.
Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.
Explore NMDA receptor modulation and its critical role in neuronal development and cognitive functions like learning and memory.
Touch a hot plate and your hand flies back. While the response is almost instant, researchers are still working to better understand the molecular mechanisms behind these sensations of heat and pain.
March 18, 2026 expert reaction to observational study on GLP-1 receptor agonists and lower risk of worsening mental illness, as published in The Lancet Psychiatry . experts commen ...
Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI - ...
Vietnam Investment Review on MSN
PRISM BioLab and Receptor AI partner on drug discovery
TOKYO, March 13, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results